Is Lipella Pharmaceuticals Stock a Good Investment?
Lipella Pharmaceuticals Investment Advice | LIPO |
- Examine Lipella Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lipella Pharmaceuticals' leadership team and their track record. Good management can help Lipella Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lipella Pharmaceuticals' business and its evolving consumer preferences.
- Compare Lipella Pharmaceuticals' performance and market position to its competitors. Analyze how Lipella Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Lipella Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lipella Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lipella Pharmaceuticals Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lipella Pharmaceuticals Common is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lipella Pharmaceuticals Stock
Researching Lipella Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 29.0% of the company outstanding shares are owned by corporate insiders. The book value of Lipella Pharmaceuticals was now reported as 1.79. The company recorded a loss per share of 4.88. Lipella Pharmaceuticals had not issued any dividends in recent years. The entity had 1:8 split on the 8th of November 2024.
To determine if Lipella Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lipella Pharmaceuticals' research are outlined below:
| Lipella Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 449.62 K. Net Loss for the year was (4.62 M) with loss before overhead, payroll, taxes, and interest of (2.36 M). | |
| Lipella Pharmaceuticals generates negative cash flow from operations | |
| Lipella Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| About 29.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group |
Lipella Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Lipella Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lipella Pharmaceuticals Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lipella Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Lipella Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lipella Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lipella Pharmaceuticals Common backward and forwards among themselves. Lipella Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Lipella Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sabby Management Llc | 2024-06-30 | 540.2 K | Vanguard Group Inc | 2024-06-30 | 34.5 K | Geode Capital Management, Llc | 2024-06-30 | 26 K | Ubs Group Ag | 2024-06-30 | 8.8 K | Tower Research Capital Llc | 2024-06-30 | 7.7 K | Bank Of America Corp | 2024-06-30 | 46.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-09-30 | 0.0 | Fmr Inc | 2024-06-30 | 0.0 | Hrt Financial Llc | 2024-06-30 | 0.0 |
Lipella Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.57 M.Market Cap |
|
Lipella Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.29) | (1.36) | |
| Return On Capital Employed | (1.49) | (1.41) | |
| Return On Assets | (1.29) | (1.36) | |
| Return On Equity | (1.47) | (1.40) |
Determining Lipella Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Lipella Pharmaceuticals is a good buy. For example, gross profit margin measures Lipella Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lipella Pharmaceuticals' profitability and make more informed investment decisions.
Basic technical analysis of Lipella Stock
As of the 29th of November, Lipella Pharmaceuticals secures the Standard Deviation of 7.86, mean deviation of 5.3, and Risk Adjusted Performance of 0.0041. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lipella Pharmaceuticals, as well as the relationship between them.Lipella Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lipella Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lipella Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lipella Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kaufman Jonathan H over six months ago Acquisition by Kaufman Jonathan H of 10000 shares of Lipella Pharmaceuticals at 0.759 subject to Rule 16b-3 | ||
Chancellor Michael B over six months ago Disposition of tradable shares by Chancellor Michael B of Lipella Pharmaceuticals subject to Rule 16b-3 | ||
Kaufman Jonathan H over six months ago Acquisition by Kaufman Jonathan H of 30000 shares of Lipella Pharmaceuticals at 0.7883 subject to Rule 16b-3 | ||
Kim Byong over six months ago Acquisition by Kim Byong of 25000 shares of Lipella Pharmaceuticals at 0.77 subject to Rule 16b-3 | ||
Chancellor Michael B over six months ago Acquisition by Chancellor Michael B of 144906 shares of Lipella Pharmaceuticals at 0.6901 subject to Rule 16b-3 | ||
Battleman David S over a year ago Acquisition by Battleman David S of 25000 shares of Lipella Pharmaceuticals subject to Rule 16b-3 |
Understand Lipella Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lipella Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0041 | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 5.3 | |||
| Coefficient Of Variation | (15,503) | |||
| Standard Deviation | 7.86 | |||
| Variance | 61.73 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (1.24) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 48.01 | |||
| Value At Risk | (8.43) | |||
| Potential Upside | 12.47 | |||
| Skewness | 1.42 | |||
| Kurtosis | 5.11 |
| Risk Adjusted Performance | 0.0041 | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 5.3 | |||
| Coefficient Of Variation | (15,503) | |||
| Standard Deviation | 7.86 | |||
| Variance | 61.73 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (1.24) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 48.01 | |||
| Value At Risk | (8.43) | |||
| Potential Upside | 12.47 | |||
| Skewness | 1.42 | |||
| Kurtosis | 5.11 |
Consider Lipella Pharmaceuticals' intraday indicators
Lipella Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lipella Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lipella Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 12th of November 2024 Other Reports | ViewVerify | |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 17th of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Lipella Stock media impact
Far too much social signal, news, headlines, and media speculation about Lipella Pharmaceuticals that are available to investors today. That information is available publicly through Lipella media outlets and privately through word of mouth or via Lipella internal channels. However, regardless of the origin, that massive amount of Lipella data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lipella Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lipella Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lipella Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lipella Pharmaceuticals alpha.
Lipella Pharmaceuticals Corporate Executives
Elected by the shareholders, the Lipella Pharmaceuticals' board of directors comprises two types of representatives: Lipella Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipella. The board's role is to monitor Lipella Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lipella Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipella Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MD | Chief CoFounder | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share 0.592 | Quarterly Revenue Growth 0.279 | Return On Assets (0.94) | Return On Equity (1.72) |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Lipella Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.